CohBar — Merger or Acquisition (May 2023)
24 slides from CohBar's merger presentation, May 23, 2023
Slide 1: CohBar
Bar INC.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the futu
Slide 3: Entered Definitive Merger Agreement
Entered Definitive Merger Agreement = Coh Bar PD Morphogenesis Inc INC, Late-Stage Clinical Immuno-Oncology Company @cohBar DP) Srexemroaenesis.ine 4
Slide 4: A Transformational Profile Going Forward
A Transformational Profile Going Forward Evolution Into a Phase 2/3-Ready Company Advancing an Innovative Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapies GS sl Targeting a number of high-value Financial strength to fund operations oncology indications through multiple key mile
Slide 5: Advancing Two Innovative Platform Technologies
Advancing Two Innovative Platform Technologies Overcoming Two Major Obstacles That Limit the Effectiveness of Cancer Immunotherapies Personalized Cancer Vaccine +> Conducted under an accelerated approval pathway for treatment of advanced Merkel Cell Carcinoma (MCC) > Lead program IFx-Hu2.0 entering
Slide 6: Transaction Highlights
Transaction Highlights ECohBar | Pi) siowmoaenesisine Merger and Financing Structured as a stock-for-stock transaction whereby all of Morphogenesis’ outstanding equity interests will be exchanged for shares of CohBar common stock. $15M PIPE from an accredited investor Expected ownership ~15% CohBar,
Slide 7: Morphogenesis Inc – James A Bianco, MD, CEO
e Y,) Morphogenesis Inc James A Bianco, MD Chief Executive Officer, Morphogenesis
Slide 8: Diversified Development Pipeline
Diversified Development Pipeline RcHiD‘o 1 Line Merkel Cell Entering Phase 2/3 registration study in Pembro +/- IFx-Hu2.0 early 2024 with data expected early 2026" Primary Checkpoint Inhibitor IFx-Hu2.0 Resistant Metastatic Cancer Entering Phase 2 study in early 2026" “Basket” Trial Personalized Can
Slide 9: Immune Fx (IFx) Personalized Cancer Vaccine
Slide 10: Personalized Cancer Vaccine
Personalized Cancer Vaccine Overcomes Primary Resistance to Checkpoint Inhibitors Lead Program (IFx-Hu2.0) High +> Demonstrated 80% systemic objective response rate +> Lead program entering Phase 2/3 registration in advanced Merkel Cell Carcinoma study in early 2024 > Excellent safety profile includ
Slide 11: Making Cancer Cells Look Like Bacteria
6 CohBer Pi) Morsnoaenesis inc Making Cancer Cells Look Like Bacteria > Intratumoral injection of nucleic acid emm55 gene encodes for immunogenic bacterial protein expressed on surface of tumor cell ~ Antigen presenting cells “educate” naive T and B cells to full complement of patient's tumor-specif
Slide 12: Primary and Secondary Epitope Spreading Provides Systemic Response
Primary and Secondary Epitope Spreading Provides Systemic Response Against All Tumor Specific Neoantigens Throughout the Body Multivalent Systemic Response Against All Into Tumor Cells of the Patient's Tumors 2° Epitope Spreading Tumor-specific T cell killing and release of “new/different” tumor ant
Slide 13: Significant Need in Advanced Merkel Cell Carcinoma (MCC)
Significant Need in Advanced Merkel Cell Carcinoma (MCC) 45% to 50% of Patients Have Primary Resistance st |j j A PD rate is 26%, 57%, 100% for those to Standard of Care, 1% line Pembrolizumab RCA ER Ea Arare type of skin cancer that usually appears as a flesh- 15 7 colored or bluish-red % =PD =non-
Slide 14: IFx-Hu2.0: Personalized Cancer Vaccine
IFx-Hu2.0: Personalized Cancer Vaccine Phase 1b Study in Advanced Merkel and Squamous Cell Carcinoma Timeline & Current Status t —Biopsy/Bie0d Status 3/15/2023 Phase 1b Primary eaeeied CES Objectve 000 N=15 f 5 4 retn20 mMCC (10), eSCC (6) im > N=9 advanced > Patients with > Assess safety > Determin
Slide 15: IFx-Hu2.0: Personalized Cancer Vaccine
IFx-Hu2.0: Personalized Cancer Vaccine Demonstrated Ability to Overcome CPI Resistance Across Multiple Tumor Types Phase 1/1b Trials in Advanced Merkel Cell, Squamous Cell, Melanoma KEY 1 DE BE Revpoweto cP PRE 2 BE Seeger azo > con sagas ate CR = Complete Response PCR = Partial Complete Response PD
Slide 16: IFx-Hu2.0: Personalized Cancer Vaccine
IFx-Hu2.0: Personalized Cancer Vaccine Overcomes 1° Resistance to PD(L)-1 Inhibitors in MCC Demonstrates Systemic Activation of Immune Response (Abscopal Effect) PARTIAL RESPONSE IFx-Hu2.0 Weekly x3 — Followed by Pembrolizumab ongoing 8+ months ‘ ’ Progression jg Three months on avelumab Injected Le
Slide 17: IFx-Hu2.0: Personalized Cancer Vaccine
IFx-Hu2.0: Personalized Cancer Vaccine Overcomes 1° Resistance to Pembrolizumab in MCC
Slide 18: IFx-Hu2.0: Phase 2/3 Registration Study Under Accelerated Approval
IFx-Hu2.0: Personalized Cancer Vaccine Phase 2/3 Registration Study Under Accelerated Approval First Line Study in Patients with Advanced Merkel Cell Carcinoma Study Expected to Commence Early 2024 1:1 Randomization, Placebo Controlled Trial tit a nfs 30-35 U.S. Enrolling ~116 IFx-Hu2.0 injections i
Slide 19: IFx-Hu3.0: mRNA Tumor Targeted Personalized Cancer Vaccine
IFx-Hu3.0: mRNA Tumor Targeted Personalized Cancer Vaccine Lead Candidate Selection in 2023 with IND-enabling Studies Expected to be Initiated in Early 2024 IFx-Hu-3.0 (emm55 mRNA) Intravenous or Autologous Whole Cell Administration > Proprietary emmS5 mRNA codon optimized for translational efficien
Slide 20: Tumor Microenvironment Modulators
Slide 21: Tumor Microenvironment: MDSCs are a Major Obstacle for Immunotherapies
Tumor Microenvironment: MDSCs are a Major Obstacle for Immunotherapies Tumor-Associated Myeloid Derived Suppressor Cells (MDSCs) are Key Drivers for Creating Immunosuppressive Environment Around Tumor by ry Produce multiple immune Promote tumor immune of cellular population in suppressive factors, t
Slide 22: Targeting Newly Identified Delta Receptor on MDSCs with Bi-Functional ADCs
Targeting Newly Identified Delta Receptor on MDSCs with Bi-Functional Antibody Drug Conjugates (ADC) +> >10-fold increase in delta receptor expression levels on tumor-associated MDSCs +> Bi-Functional ADCs link highly specific delta receptor inhibitor to checkpoint inhibitor = Reprograms MDSCs to M-
Slide 23: Upcoming Value-Driving Milestones
Upcoming Value-Driving Milestones 1st Line Merkel Cell IFx-Hu2.0 sembro +/- IFx-Hu2,0 Primary CPI Resistant [Fx-Hu2.0 Metastatic Cancer "Basket" Trial Personalized Cancer Vaccine: Intravenous Targeted (mRNA emm55) IFx-Hu3.0 ‘ nae (DLBCL ) Tumor Microenvironment Modulators: MDSC Bi-Functional Inhibit
Slide 24: Two Innovative Technology Platforms with Ability to Target Multiple Indications
Two Innovative Technology Platforms with Ability to Investment Summary Target Multiple High Value Oncology Indications Proposed Merger to Transform into Phase 2/3-Ready Company Advancing Innovative Pipeline of Entering Phase 2/3 Therapies to Overcome Cancer Demonstrated registration study in Immunot